Company intelligence / Profile preview

Affinivax

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Affinivax’s lead 24-valent pneumococcal MAPS vaccine (also referenced as ASP3772/AFX3772) completed Phase 1 in adults showing safety and high immunogenicity, with an adult Phase 2 study completed and analyses ongoing, and pediatric studies (toddlers) initiated; the program has FDA Breakthrough Therapy designation and is preparing for Phase 3 under GSK.[2][3]

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineProteinRecombinant protein
Industry: Biotech

Partnerships

GSKAstellas PharmaBoston Children’s HospitalBill & Melinda Gates Foundation

Beyond the preview

Go deeper on Affinivax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Affinivax.

Explore the full profile